Follow
Kieran Docherty
Title
Cited by
Cited by
Year
Dapagliflozin in patients with heart failure and reduced ejection fraction
JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ...
New England Journal of Medicine 381 (21), 1995-2008, 2019
60192019
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
SL Kristensen, R Rørth, PS Jhund, KF Docherty, N Sattar, D Preiss, ...
The lancet Diabetes & endocrinology 7 (10), 776-785, 2019
13222019
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
M Vaduganathan, KF Docherty, BL Claggett, PS Jhund, RA de Boer, ...
The Lancet 400 (10354), 757-767, 2022
5262022
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ...
Jama 323 (14), 1353-1368, 2020
4852020
Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial
MN Kosiborod, PS Jhund, KF Docherty, M Diez, MC Petrie, S Verma, ...
Circulation 141 (2), 90-99, 2020
3552020
Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)
MMY Lee, KJM Brooksbank, K Wetherall, K Mangion, G Roditi, ...
Circulation 143 (6), 516-525, 2021
3332021
Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF
PS Jhund, SD Solomon, KF Docherty, HJL Heerspink, IS Anand, M Böhm, ...
Circulation 143 (4), 298-309, 2021
2632021
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
PS Jhund, T Kondo, JH Butt, KF Docherty, BL Claggett, AS Desai, ...
Nature medicine 28 (9), 1956-1964, 2022
2122022
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
KF Docherty, PS Jhund, SE Inzucchi, L Køber, MN Kosiborod, FA Martinez, ...
European heart journal 41 (25), 2379-2392, 2020
1942020
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
JP Curtain, KF Docherty, PS Jhund, MC Petrie, SE Inzucchi, L Køber, ...
European heart journal 42 (36), 3727-3738, 2021
1672021
Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF
AM Jackson, P Dewan, IS Anand, J Bělohlávek, O Bengtsson, RA de Boer, ...
Circulation 142 (11), 1040-1054, 2020
1672020
Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction
DD Berg, PS Jhund, KF Docherty, SA Murphy, S Verma, SE Inzucchi, ...
JAMA cardiology 6 (5), 499-507, 2021
1662021
Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short-and long-term outcomes
E Platz, RT Campbell, B Claggett, EF Lewis, JD Groarke, KF Docherty, ...
JACC: Heart Failure 7 (10), 849-858, 2019
1612019
Statin treatment of children with familial hypercholesterolemia–trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a …
A Vuorio, KF Docherty, SE Humphries, J Kuoppala, PT Kovanen
Atherosclerosis 226 (2), 315-320, 2013
1252013
Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
P McEwan, O Darlington, JJV McMurray, PS Jhund, KF Docherty, M Böhm, ...
European journal of heart failure 22 (11), 2147-2156, 2020
1172020
Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF
KF Docherty, M Vaduganathan, SD Solomon, JJV McMurray
Heart Failure 8 (10), 800-810, 2020
1162020
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
M Serenelli, M Böhm, SE Inzucchi, L Køber, MN Kosiborod, FA Martinez, ...
European heart journal 41 (36), 3402-3418, 2020
1152020
Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF
L Shen, SL Kristensen, O Bengtsson, M Böhm, RA de Boer, KF Docherty, ...
Heart Failure 9 (4), 254-264, 2021
1052021
Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction: a post hoc analysis of the DAPA-HF trial
JH Butt, P Dewan, B Merkely, J Belohlávek, J Drożdż, M Kitakaze, ...
Annals of internal medicine 175 (6), 820-830, 2022
862022
Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF
C Adamson, KF Docherty, HJL Heerspink, RA de Boer, K Damman, ...
Circulation 146 (6), 438-449, 2022
832022
The system can't perform the operation now. Try again later.
Articles 1–20